-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The R&D investment in 2019 was US$142 million, the R&D investment in 2020 was US$222 million, and the R&D investment in the first half of 2021 was US$346 million.
This is Zai Lab's increasingly steep R&D growth rate
.
Today, Zai Lab's R&D degree of "willingness" is second only to the two "first brothers" Hengrui and Baekje in R&D in the pharmaceutical industry
Zai Lab, which was founded only 7 years ago, has grown into a leader among contemporary innovative pharmaceutical companies
.
So far, Zai Lab has built a pipeline of more than 25 products, of which 12 products are in late clinical stages, 3 products have been launched in China, and 5 products have been approved in the United States; and a team of more than 1,600 people covering the world.
Zai Lab's R&D laboratory in the U.
S.
01 Vision: Zai Lab moves towards the 3.
0 stage
0 stage
In the past five years, China's entire biomedicine industry structure has undergone earth-shaking changes
.
The competitive landscape of domestic pharmaceutical companies has also taken two different routes after 2015
Dr.
Xu Ning, Executive Vice President of Zai Lab, Head of Clinical Operations
Xu Ning, Executive Vice President and Head of Clinical Operations of Zai Lab, was impressed by this.
“When Zai Lab was established in early 2014, we had only a dozen people, but Zai Lab has already begun to prepare and build a R&D laboratory in Shanghai.
Suzhou’s GMP production plant, as well as our clinical research and product production quality management system and drug safety management system, are determined to build Zai Lab into a biopharmaceutical company with innovation as the core
.
” “Zai Lab’s short-term goal is China to focus on the needs of the patient, the foreign good product quickly into China, and quickly make good drug benefit Chinese patients, which is again the target of 1.
Dr.
Yan Shuizhong, Chief Operating Officer of Zai Lab Research and Development
Yan Shuizhong, chief operating officer of Zai Lab's research and development field, also stated that the research and development of innovative drugs is a systematic project.
When Zai Lab was founded, the approval environment for new drugs in China was very different from now.
In China, patients' demand for some innovative clinical therapies is very urgent
.
"But the reality is that there is a misallocation of resources.
Some overseas small and medium-sized biotech companies may have some good products in their hands, but they are not capable of global development, let alone carry out corresponding clinical studies for Chinese patients, and related innovative products.
It’s been too late to enter China
.
The most representative example at this stage is Nirapali, which is China’s first locally-produced PARP inhibitor.
Using License-in to rapidly expand the pipeline, Zai Dao has a great reputation in the pharmaceutical industry for a time
.
What the outside world does not know is that Zai Lab established an internal R&D team in the early days of its establishment.
"Zai Lab's mid-term goal is to lead the development of new indications in pipeline products or explore new combination therapies based on clinical needs on the one hand, and on the other hand to promote the early stage products of our own research and development and external cooperation to the clinic
.
" This is the goal of Zai Lab 2.
"In fact, we have now entered the third stage.
" Xu Ning stated that the goal of Zai Lab 3.
0 is to promote the world's first-of-its-kind or best-in-class results with global intellectual property rights
.
At the same time, Zai Lab will continue to strengthen cooperation with partners and academic institutions to further expand globally
02 Zai Lab's next stop: Where to go?
02 Zai Lab's next stop: Where to go? The water is big and the fish is big, how can Zai Lab, which is moving towards the 3.
0 stage, stand out again?
On the recent R&D day, Zai Lab announced a milestone to be reached in 2025: It is expected to have more than 15 listed products in 2025, covering more than 35 indications, and aspire to become a leading global biomedical company
.
In terms of self-research capacity building, at least one global IND (Clinical Application for New Drug) will be generated every year by 2025
.
Compared with the current stage, this goal means that Zai Lab will bring more than 12 products to the market in the next four years
.
What deserves more attention is Zai Lab's goal of independent research and development-at least one global IND every year after 2025
.
How to achieve?
Zai Lab will continue to expand and deepen based on the open innovation model, especially relying on the rich internal expertise, combined with the highly unmet clinical needs in China, and discuss with partners how to develop more indications and lead some Differentiated development of indications, including combination therapy, etc.
, to find more and better treatment methods for patients
.
Xu Ning gave an example: For example, in the field of autoimmunity, Zai Lab will lead the global exploration of new indications in the research pipeline efgartigimod, as well as the key research for global approval in the future
.
For another example, in the field of gastrointestinal tumors, Zai Lab and its partners have jointly completed the global phase II clinical study of bemarituzumab, a product targeting FGFR2b.
China also enrolled the world's first patient at the time, and ultimately contributed a quarter of the total Patient
.
This product will be the first of its kind in China
.
bemarituzumab has now obtained breakthrough therapy qualifications in both China and the United States
.
Cooperation is what Zai Lab is best at.
Through cooperation, Zai Lab continues to move towards the source of innovation
.
Several recent collaborations reached by Zai Lab are also intended to synergistically strengthen internal R&D capabilities.
For example, through cooperation with RubrYc, it has further strengthened the antibody R&D platform and increased the diversity of antibodies; cooperated with MacroGenics, using their DART platform, Early research and development cooperation on immuno-oncology molecules including double antibodies
.
Through cooperation with Schrödinger, advance drug research and development in the field of DNA damage response.
.
.
In the future, Zai Lab-related self-developed products will go out.
Xu Ning said, “We will conduct global development for these first-of-its-kind or potential best-in-class products.
Of course, it also includes international cooperation with large companies in the global region.
Maybe
.
"
